Was Rova-T Worth The High Price To AbbVie?
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma presented early-stage data for its antibody-drug conjugate at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago that showed promise for the drug in a small subset of patients with small cell lung cancer, but had disappointing results for the overall population.
You may also be interested in...
AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments
At J.P. Morgan, AbbVie said the clinical struggles of Rova-T won’t alter its deal-making plans and leave it with plenty of solid tumor possibilities. The pharma took a $4bn write-off of the Stemcentrx deal on Jan. 4.
Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions
Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data in third-line small cell lung cancer threaten Rova-T's viability for approval.
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.